Research progress on nanoparticle albumin-bound paclitaxel

YIN Xiao-dong,YAO Qiang,LI Wei-lian
DOI: https://doi.org/10.3969/j.issn.1672-4992.2011.07.66
2011-01-01
Journal of Modern Oncology
Abstract:Nanoparticle albumin-bound paclitaxel is a novel formulation of paclitaxel that does not require the synthetic solvent carrier used with other taxanes.It is given as a 30 min intravenous infusion without corticosteroid or antihistamine premedication.It exploits the natural properties of albumin to increase uptake and accumulation of paclitaxel in the tumor through gp60-mediated endothelial transcytosis,and interaction with the albumin-binding protein SPARC(secreted protein,acidic and rich in cysteine).Preclinical models have shown that nab-paclitaxel has greater antitumor activity than solvent-based paclitaxel and that lead to the clinical testing of nab-paclitaxel in chemotherapy on the patients with malignant tumors.Some results are made us inspiring.
What problem does this paper attempt to address?